DURECT Corporation (DRRX): Price and Financial Metrics


DURECT Corporation (DRRX)

Today's Latest Price: $2.10 USD

0.07 (-3.23%)

Updated Jul 10 4:00pm

Add DRRX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 213 in Medical - Pharmaceuticals

See all "A" rated Strong Buy stocks

DRRX Stock Summary

  • With a one year PEG ratio of 589.49, Durect Corp is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 93.68% of US stocks.
  • Price to trailing twelve month operating cash flow for DRRX is currently 105.63, higher than 97.21% of US stocks with positive operating cash flow.
  • With a price/sales ratio of 14.59, Durect Corp has a higher such ratio than 90.76% of stocks in our set.
  • Stocks that are quantitatively similar to DRRX, based on their financial statements, market capitalization, and price volatility, are TNAV, INFI, AKBA, ACIU, and ORMP.
  • Visit DRRX's SEC page to see the company's official filings. To visit the company's web site, go to www.durect.com.
DRRX Daily Price Range
DRRX 52-Week Price Range

DRRX Stock Price Chart Technical Analysis Charts


DRRX Price/Volume Stats

Current price $2.10 52-week high $3.95
Prev. close $2.17 52-week low $0.64
Day low $2.02 Volume 1,033,096
Day high $2.18 Avg. volume 1,559,957
50-day MA $2.34 Dividend yield N/A
200-day MA $2.06 Market Cap 411.65M

DURECT Corporation (DRRX) Company Bio


DURECT Corporation, a specialty pharmaceutical company, focuses on the development of pharmaceuticals products based on its proprietary drug formulations and delivery platform technologies in the United States, Europe, Japan, and internationally. The company was founded in 1998 and is based in Cupertino, California.

DRRX Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target:Forecasted Gain:
$2.10$3.5360%

We started the process of determining a valid price forecast for Durect Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Durect Corp ranked in the 58th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. In terms of the factors that were most noteworthy in this DCF analysis for DRRX, they are:

  • The company has produced more trailing twelve month cash flow than merely 9.1% of its sector Healthcare.
  • Durect Corp's effective tax rate, as measured by taxes paid relative to net income, is at 0 -- greater than only 0% of US stocks with positive free cash flow.
  • Durect Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -8.5. This coverage rate is greater than that of merely 9% of stocks we're observing for the purpose of forecasting via discounted cash flows.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%57%
1%58%
2%60%
3%61%
4%63%
5%65%

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as DRRX, try UTHR, MEDP, HNGR, QDEL, and UNH.


DRRX Latest News Stream


Event/TimeNews Detail
Loading, please wait...

DRRX Latest Social Stream


Loading social stream, please wait...

View Full DRRX Social Stream

Latest DRRX News From Around the Web

Below are the latest news stories about Durect Corp that investors may wish to consider to help them evaluate DRRX as an investment opportunity.

Is It Too Late to Buy These 3 Pharmaceutical Stocks?

Relmada Therapeutics, Neoleukin Therapeutics, and Durect were among the fastest-rising pharmaceutical stocks over the past year.

Yahoo | July 7, 2020

DURECT Corporation Announces Initiation of Patient Recruitment in Phase 2 Safety and Efficacy Study of DUR-928 in COVID-19 Patients with Acute Liver or Kidney Injury

DURECT Corporation (Nasdaq: DRRX) today announced it has initiated recruiting patients for its randomized, double-blind, placebo-controlled, multi-center Phase 2 study to evaluate the safety and efficacy of DUR-928 in hospitalized COVID-19 infected patients with acute liver or kidney injury. The primary efficacy endpoint is a composite of survival and being free of acute organ failure at Day 28. The trial will enroll approximately 80 patients.

Yahoo | July 1, 2020

DURECT Corporation Joins the Russell 3000® Index

DURECT Corporation (Nasdaq: DRRX) today announced that it is set to join the broad-market Russell 3000® Index as a result of the 2020 Russell indexes annual reconstitution, effective after the US stock market opens today, June 29, 2020.

Yahoo | June 29, 2020

U.S. FDA seeks more data on Heron Therapeutics' non-opioid painkiller

Yahoo | June 29, 2020

Gilead terminates agreement with DURECT

DURECT announces Gilead Sciences will terminate the License Agreement in July 2019, effective December 22, for the development and commercialization of a long-acting injectable HIV investigational product utilizing DURECT's SABER technology.DURECT anticipates recognizing remaining deferred revenue of ~$23.1M Q2 of 2020, associated with the receipt of the upfront license and development milestone payment.(DRRX) is...

Seeking Alpha | June 26, 2020

Read More 'DRRX' Stories Here

DRRX Price Returns

1-mo -1.87%
3-mo N/A
6-mo -13.93%
1-year 217.22%
3-year 25.00%
5-year -16.67%
YTD -44.74%
2019 691.67%
2018 -47.83%
2017 -31.34%
2016 -39.37%
2015 179.75%

Continue Researching DRRX

Here are a few links from around the web to help you further your research on Durect Corp's stock as an investment opportunity:

Durect Corp (DRRX) Stock Price | Nasdaq
Durect Corp (DRRX) Stock Quote, History and News - Yahoo Finance
Durect Corp (DRRX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9653 seconds.